Serum Proteome Changes Following HIV Infection by Haarburger, David Richard
  
 
 
 
 
 
 
The copyright of this thesis rests with the University of Cape Town. No 
quotation from it or information derived from it is to be published 
without full acknowledgement of the source. The thesis is to be used 
for private study or non-commercial research purposes only. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
   
 
 
 
Serum Proteome Changes Following HIV 
Infection 
 
by 
 
STUDENT: DAVID RICHARD HAARBURGER 
STUDENT NUMBER: HRBDAV002 
 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In partial fulfillment of the requirements for the degree 
 
MMed (Chemical Pathology) 
 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
 
Date of submission:  5 March 2010 
 
Supervisor:  Prof T S Pillay  
Division of Chemical Pathology 
University of Cape Town 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   1 
Declaration 
 
 
 
I, David Richard Haarburger, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements 
indicate otherwise) and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the 
whole or any portion of the contents in any manner whatsoever. 
 
Signature: ………………………………… 
 
Date:   ……………………………………. 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   2 
Table of Contents 
 
Declaration ..........................................................................................................1 
Table of Contents ................................................................................................2 
Acknowledgements .............................................................................................5 
List of Abbreviations ..........................................................................................6 
PART A................................................................................................... 8 
Protocol ...............................................................................................................9 
Principal Investigator ........................................................................................9 
Project Title ....................................................................................................10 
Short Description of the Project.......................................................................10 
Collaborators...................................................................................................10 
Project Details.................................................................................................11 
Aim and objectives......................................................................................11 
Background.................................................................................................11 
Detailed methodology .................................................................................13 
References...................................................................................................14 
Envisaged outputs/outcomes........................................................................15 
Impact.............................................................................................................15 
Institutional Approval .....................................................................................16 
Funding...........................................................................................................16 
Amendments to Original Protocol....................................................................17 
PART B................................................................................................. 18 
Literature Review: Biomarker discovery in HIV ............................................19 
Introduction ....................................................................................................19 
Proteomics ......................................................................................................19 
Proteomic Techniques .....................................................................................20 
Protein separation........................................................................................20 
Protein visualisation ....................................................................................21 
Protein identification ...................................................................................22 
Biomarkers......................................................................................................23 
U
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   3 
HIV.................................................................................................................24 
HIV Proteomic Research.................................................................................25 
Virions ........................................................................................................25 
Macrophage secretions ................................................................................26 
Cerebrospinal fluid......................................................................................26 
Serum or plasma..........................................................................................27 
Brain microvascular endothelial cells ..........................................................27 
T-cells .........................................................................................................28 
Cervical lavage samples ..............................................................................29 
Conclusion......................................................................................................29 
References ......................................................................................................30 
PART C................................................................................................. 34 
Manuscript for Submission to the Journal of Proteome Research...................35 
Synopsis..........................................................................................................35 
Author List......................................................................................................36 
Abstract ..........................................................................................................36 
Keywords........................................................................................................37 
Introduction ....................................................................................................37 
Materials and Methods ....................................................................................38 
Results ............................................................................................................41 
Discussion.......................................................................................................42 
Conclusion......................................................................................................45 
Acknowledgment ............................................................................................45 
References ......................................................................................................45 
Tables .............................................................................................................50 
Table1.  List of differentially expressed proteins .........................................50 
Table 2.  Identification of differentially expressed spots ..............................51 
Figures ............................................................................................................52 
Figure 1.  Representative 2D-gels from each group .....................................52 
Supporting Information....................................................................................54 
Health Questionnaire.......................................................................................54 
Journal of Proteome Research: Instructions to Authors.................................56 
General guidelines for manuscript preparation.............................................57 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   4 
Elements of a Manuscript ............................................................................58 
Manuscript types .........................................................................................62 
File preparation for manuscript revisions.....................................................64 
Acceptable word-processing packages.........................................................65 
PART D................................................................................................. 66 
University of Cape Town Dissertation Guidelines...........................................67 
Minimum Requirements for Dissertations for MMed and MPhil for 
Subspecialities Degrees...................................................................................67 
Research Protocol........................................................................................67 
Submission of Dissertations ........................................................................68 
The Dissertation ..........................................................................................69 
Examiners ...................................................................................................71 
Consent Form (English)....................................................................................73 
Consent Form (Xhosa) ......................................................................................75 
Phlebotomy Protocol.........................................................................................78 
Ethics Approval.................................................................................................80 
Supplementary Figures.....................................................................................81 
Figure S1. Gels from HIV-positive subjects.................................................81 
Figure S2.  Gels from HIV-negative subjects...............................................82 
Mass Spectrometry Data...................................................................................83 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   5 
Acknowledgements 
 
I would like to thank the following people for their contributions, without which this 
thesis would not be possible: 
 
LINDA GAIL-BECKER For using her resources and those of the Desmond 
Tutu HIV Centre’s to find suitable subjects for me 
 
JÖRGEN BERGSTRÖM For sharing his expertise on two-dimensional gels 
and mass spectrometry 
 
COLLEEN HERMAN For giving me access to Masiphumelele Clinic and 
its patients 
 
WAN IRYANI WAN ISMAIL For teaching me basic laboratory techniques 
 
JUDY KING For her constant availability, excellent advice and 
endlessly correcting my manuscripts 
 
TAHIR PILLAY For his introduction and guidance on this project, a 
field I would otherwise never have come in 
contact 
  
SIBONGILE SIGIWA For acting as community liaison, counsellor,  and 
phlebotomist 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   6 
List of Abbreviations 
 
2DE  Two--Dimensional gel electrophoresis 
2D-Gel Two-dimensional gel 
A1AG  Alpha-1-acid glycoprotein 
AIDS  Acquired immunodeficiency syndrome 
ALT  Alanine transaminase 
ANOVA Analysis of variance 
ApoAI  Apolipoprotein A-1 
ASMP  Abnormal spindle-like microcephaly-associated protein 
CD4  Cluster designation 4 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CRP  C-Reactive protein 
CSF  Cerebrospinal fluid 
DTT  Dithiothreitol 
ESI  Electrospray ionization 
HAD  HIV-associated dementia 
HAND  HIV-associated neurocognitive disorder 
HIV  Human immunodeficiency virus 
IEF  Isoelectric focusing 
IgG  Immunoglobulin G 
IPG  Immobilised pH gradient 
LC  Liquid-chromatography  
MALDI Matrix-assisted laser desorption ionization 
MMP9  Matrix metalloproteinase 9  
MS  Mass spectrometer/Mass spectrometry  
MSDB  Mass Spectrometry protein sequence database 
NCBI  National Centre for Biotechnology Information 
SDS  Sodium dodecyl sulfate 
T2CK1 Type II cytoskeletal keratin 1 
TCEP  Triscarboxyethyl phosphine 
TFA  Trifluoroacetic acid 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   7 
TOF  Time of flight 
Tris  Trishydroxymethylaminomethane 
 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   8 
 
 
PART A 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   9 
Protocol 
 
 
ORIGINAL PROTOCOL AS APPROVED BY THE DEPARTMENTAL 
RESEARCH COMMITTEE AND FACULTY RESEARCH ETHICS 
COMMITTEE 
 
 
Principal Investigator 
Academic Pathology Department: Chemical Pathology 
 
Principal Investigator 
 
Tahir Pillay: Chief Specialist, Professor & Head, Division of 
Chemical Pathology 
Groote Schuur and Red Cross Children’s 
Hospitals 
    University of Cape Town 
    MP 0275905 
    profts.pillay@uct.ac.za 
    Tel: 021 406 6185 
  
Project Leader  
 
David Haarburger:  Registrar 
     National Health Laboratory Service 
     Division of Chemical Pathology 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   10 
University of Cape Town and Groote Schuur 
Hospital 
     MP 0576549 
     david.haarburger@uct.ac.za 
     Tel: 021 404 4135 
 
Degree registered:   MMed(Chemical Pathology)   
Year initially registered:  2006  
Current year of registration: 2 
 
Project Title  
 
Biomarker discovery in HIV/AIDS using proteomics. 
 
Short Description of the Project  
 
The objective of this project is to use proteomics to identify differentially expressed 
proteins in serum from patients with HIV in the hope of detecting novel biomarkers 
for HIV/AIDS and associated complications. Samples will be obtained from HIV 
clinics and vaccine centres associated with the Desmond Tutu HIV Centre, UCT and 
analyzed using proteomic techniques in collaboration with the Swegene Proteomics 
Centre.  The proteome of HIV positive serum will be compared with the proteome of 
HIV negative serum. Biomarkers identified in this way will be characterised further 
for specificity using immunoassays. 
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Project Details 
 
Aim and objectives  
The specific objectives of this project are to: 
a) Establish a base of proteomics expertise as it applies to diagnostic clinical 
chemistry, in the Division of Chemical Pathology at the University of Cape 
Town and GSH NHLS laboratory and in the long-term within the broader 
context of the greater NHLS. 
b) Use proteomics as a basis to identify new biomarkers in HIV infection and 
eventually in other diseases of national priority; 
c) Create a link between basic and applied research; 
d) Make a meaningful contribution to research capacity development; 
e) Foster long-term links with other institutions in the NHLS umbrella; 
f) Use this information from this project to develop and commercialize new 
immunoassays under the NHLS umbrella. 
 
Background 
The burden of HIV/AIDS on health services and economies worldwide and 
especially in Africa cannot be overstated.  Currently, the diagnosis of HIV is 
dependent on the detection of viral protein or antiviral antibody in human serum 1, 2 
or more recently, the detection of viral nucleic acid in serum. CD4+ cells and viral 
load can also be used as a marker of disease progress and to monitor response to 
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antiretroviral therapy.1, 2  It will be useful to be able to identify protein markers that 
are induced during HIV infection and can be used to diagnose and monitor disease 
progression and the complications of therapy.  
Proteomics is thus the study of the large-scale expression, function, and interaction 
of the complement of proteins in an organism in health and disease.3  Recent 
advances in proteomic technologies permit the evaluation of systematic changes in 
protein expression in response to intrinsic or extrinsic perturbations to the biologic 
system, for example, those that occur in infectious diseases.  Proteomics is a 
potential tool for the discovery and application of novel biomarkers in diagnosis of 
the inception and progression of diseases, which might then affect prevention and 
therapy.  Serum proteome analysis has the potential to facilitate disease diagnosis 
and monitoring.4  Previous studies have shown that this is a formidable approach to 
identify new biomarkers, especially in the field of cancer research.  
 
Proteomics has emerged as a relatively new field of protein science based on a 
“classical” electrophoretic technique and is now dominated by separation methods 
including traditional 2-D electrophoresis and liquid chromatography to separate 
proteins, and methods to analyse proteins by mass spectrometry.5  Coupled with 
bioinformatics and rapidly evolving software, these techniques have become 
powerful methods for protein characterization and identification. In the diagnostic 
arena, these techniques have been used to characterize protein profiles from normal 
and diseased body fluids.4, 6  Blood has direct contact with almost all of the tissues in 
the human body and therefore pathological changes are likely to be reflected by 
proteomic changes in serum. Biomarkers identified in serum may form the basis for 
simple, non-invasive diagnostic or monitoring tests. There have been a number of 
developments in proteomics which have enhanced its utility beyond the research lab. 
Proteomic analysis is being applied to the identification of biomarkers in a number 
of other disease states.7-9  Proteomic analysis of human serum for identification of 
disease-specific biomarkers promises to be a powerful diagnostic tool for defining 
the onset, progression and prognosis of human diseases.4, 10-12  Serum provides an 
abundant sample for diagnostic analyses because of the expression and release of 
proteins (potential biomarkers) into the bloodstream in response to specific 
physiological states such as viral infections, bacterial infections, cancer and 
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Alzheimer’s disease to name a few. Therefore, serum offers a medium to define 
differential expression characteristics specific to those physiological states. 
 
The aim of this study is to use proteomics to identify novel proteins that are induced 
in the human serum proteome following HIV infection and the development of 
AIDS. 
 
Detailed methodology 
This project has been approved by the UCT Research Ethics Comitee (Rec Ref 
211/2007).  The project will be conducted between August 2007 and June 2009.  
Volunteers will be selected from patients visiting the HIV clinics and vaccine centres 
associated with the Desmond Tutu HIV Centre. Serum will be obtained by 
venepuncture from 30 HIV positive and 30 HIV negative Xhosa men aged between 
twenty-one and thirty-five.  All volunteers will not be on any medication and will not 
have a history of any systemic illness.  A creatinine, alanine transaminase, C-reactive 
protein and a random glucose will be done on all samples to rule out disease.  All of 
these samples will be suitably anonymised. Albumin and immunoglobulins make up 
more than 70% of the proteins in human serum. Albumin and IgG will be depleted 
from the serum using the ProteoPrep Blue Albumin depletion kit (Sigma Chemical 
Company). The depleted sample will then be subjected to isoelectric focussing and 
SDS gel electrophoresis using the Ettan IPGphor and Ettan DALT II (Amersham 
Biosciences/GE Healthcare). The gels will then be stained with fluorescent stains 
such as Sypro Ruby. Alternative the proteins can be fluorescently labelled with 
CyDyes. The gels will be scanned and analysed to identify differentially abundant 
protein spots using relevant software (eg ImageQuant software by GE Healthcare).  
The statistical significance of differences in the intensity of protein spots will be 
determined using t-tests on the gels in each group.  Protein spots with a relative ratio 
of > 1,5 and a t-test value <0,05 will be considered significant. 
  
Differentially expressed protein spots will be subjected to robotic in-gel digestion 
(Ettan Spot Handling Workstation) using trypsin after reduction with DTT and 
alkylation with iodoacetamide. A portion of the resulting digest supernatant will be 
used for matrix assisted laser ionization desorption mass spectrometry (MALDI-MS) 
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analysis. Spotting will be performed robotically (ProMS) with ZipTips and peptides 
will be eluted from the C18 material with matrix (R-cyano 4-hydroxy cinnamic acid) 
in 60% acetonitrile, 0.2% TFA. MALDI-MS data will be acquired on an Applied 
Biosystems Voyager DE-STR instrument and the observed m/z values will be 
submitted to ProFound for peptide mass fingerprint searching using the NCBI 
nonredundant database. Those samples that proved inconclusive following MALDI-
MS will be analyzed by LC/MS/MS on a Micromass Q-Tof Ultima. The MS/MS 
data will be used for database search using MASCOT software (Matrix Science). 
 
All of the mass spectrometric analysis will be carried out in Sweden at the University 
of Goteborg in collaboration with Dr Jörgen Bergström. The samples will be 
collected and prepared in Cape Town. 
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Envisaged outputs/outcomes 
It is envisaged that this study will elucidate some of the proteomic changes 
associated with HIV and help identify possible target proteins which will provide the 
basis for developing immunoassays to monitor the severity of HIV infection and 
monitor the complications. The work will be presented at the South African Society 
of Pathologists annual meeting, the annual conference of the Association for Clinical 
Biochemistry (UK) and the American Association of Clinical Chemistry (USA).  The 
study will provide material for Dr Haarburger’s MMed dissertation and will provide 
Dr Haarburger with the opportunity to publish in a major peer-reviewed journal such 
as Journal of Clinical Pathology or Clinical Chemistry.  
 
Impact 
Dr Haarburger will be the project leader. He is currently training as a Registrar in 
Chemical Pathology and is registered for the MMed Degree at UCT. The project will 
establish a base of proteomics expertise as it applies to diagnostic clinical chemistry, 
in the Division of Chemical Pathology at the University of Cape Town.  The project 
will form an adjunct for collaboration with the University of Gotheborg in Sweden 
and will therefore be important for enhancing institutional capacity.   Furthermore, 
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the project will develop capacity in a new and emerging area that is under-researched 
in the South African context. 
 
Institutional Approval 
This proposal has been approved by the University of Cape Town Research Ethics 
Committee. 
 
Funding 
Funding is provided by the National Health Laboratories Research Trust  
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Amendments to Original Protocol 
 
1 Title – The project title was changed from Biomarker discovery in HIV/AIDS 
using proteomics to Serum proteome changes following HIV infection to 
more accurately reflect the research. 
 
2 Gel staining – Due to the unavailability and high cost of fluorescent 
scanners, fluorescent dyes could not be used.  Silver staining was used as an 
alternative. 
 
3 Mass spectrometric analysis – Due to the difficulties in transporting 
biological samples, samples were analysed at the Centre for Proteomic and 
Genomic Research, Institute of Infectious Diseases and Molecular Medicine, 
Faculty of Health Sciences, University of Cape Town and not at the Swegene 
Proteomics Centre, University of Goteborg, Lund, Sweden. 
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 Literature Review: Biomarker discovery in HIV  
 
 
Biomarker discovery in HIV using proteomics 
 
Introduction 
Proteomics involves the analysis of the full array of proteins produced by an 
organism.  Over the last two decades, new techniques have revolutionised the task of 
determining a proteomic profile.  Since the Human Immunodeficiency Virus (HIV) 
pandemic currently affects almost 40 million people, and has been responsible for the 
death of over 25 million, it is logical to ask what role proteomics can play in 
understanding and overcoming this disease. The intent of this review is to assess the 
current state of proteomic techniques and its application to HIV research.  Some of 
the contributions of proteomics to our current understanding of the pathogenesis of 
HIV infection will be highlighted, as well as the role of biomarkers in disease and 
their potential role in monitoring HIV. 
 
Proteomics 
Proteomics can be defined as the study of the full set of proteins expressed by an 
organism, tissue or cell, and the change in their expression patterns under different 
conditions.  Proteomic techniques initially developed in the 1990’s from analytical 
biochemical techniques used for protein separation and have evolved to provide the 
researcher with a set of new tools to help understand biological processes at the 
molecular level.   Although great strides have been made since then with the 
currently available genomic toolbox and associated bioinformatic tools,  these 
techniques had several limitations.1  Understanding the biology of cells at the genetic 
level is not always equivalent to understanding it at the protein level, and this is 
crucial since it is the proteins that are the functional molecules of the cell. 
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Proteomics has been used to identify proteins involved in pathological processes and 
to evaluate changes in protein expression during illness.  A major focus of clinical 
proteomics has been cancer research but the techniques are equally valid when 
studying infectious diseases.  Proteomic methods can be used in various ways to 
study infectious diseases.  For example, the pathogen itself may be studied, the host 
or immune response to the pathogen can be examined, or the mechanism of action of 
antimicrobials can be determined.  A vast amount of research has also been applied 
to the development of biomarkers for the diagnosis of diseases and for the 
monitoring of their progress.   
 
Proteomic Techniques 
Proteomics uses a combination of several techniques including electrophoresis, 
image analyses, mass spectrometry (MS), amino acid sequencing and bio-informatics 
to comprehensively resolve, quantify and characterise proteins.2  The main steps 
involve protein separation, quantification, if relevant, and protein identification. 
 
Protein separation 
For analysis of proteomes, protein separation has traditionally been performed by 2-
dimensional gel electrophoresis (2DE).  This technique was first described in 1975,3, 
4  and dominated proteomics for the following 25 years.  It involves a primary 
separation based on the isoelectric point of individual proteins called isoelectric 
focusing, followed by a secondary separation based on protein size using 
polyacrylamide gels. 2DE has many advantages.  It is an efficient and versatile 
method and has been used for the separation of complex protein mixtures.5  It 
produces high-resolution separation and allows for protein quantification both within 
a sample and between samples.6  It is reproducible and sensitive, and under the 
appropriate conditions has been able to resolve over 10 000 proteins.7 
 
However, 2DE has its limitations.  Despite its impressive resolution, it is still not 
adequate considering the enormous diversity of cellular proteins, and comigrating 
proteins in the same spot are not uncommon.8  Thus, zoom or narrow pH range gels 
are required to increase the resolution and to greatly decrease the probability of this 
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problem.9  Some proteins, such as membrane and nuclear proteins, are poorly water-
soluble and tend to precipitate during isoelectric focusing. Recent advances have 
improved the situation, but it appears that this will remain a major limitation of 
2DE.6 
 
Proteins in human tissues have a huge dynamic range. In serum for instance, albumin 
is present at 40 g/L and cytokines at ng/L levels (109 dynamic range).  This is clearly 
out of the range of 2DE which has a maximum dynamic range of  104.6  Proteins are 
heterogeneous and cover a wide range of isoelectric points and masses.  No single 
gel can routinely cover all the proteins.  These problems, of course, are not unique to 
2DE and will complicate all separation techniques.  What is unique to 2DE is the fact 
that it is costly, labour-intensive and not easily automated.10 
 
In an attempt to overcome some of these limitations, alternative protein separation 
methods have been developed.  These include: one-dimensional gel electrophoresis 
followed by mass spectroscopy analysis;6 electrophoresis-free, liquid 
chromatography (LC)-based approaches such as multi-dimensional protein 
identification technology (MUDPIT);11 or isotope-coded affinity tags (ICAT).12  
Each of these methods has its own advantages and disadvantages.  
 
Protein visualisation 
Several stains can be used to visualise proteins after 2DE, each with its own benefits 
and drawbacks.  The more commonly used stains are Coomassie brilliant blue 
(detection limit 8-18 ng) and silver staining (detection limit 2-4 ng).2  In addition, 
fluorescent dyes can be used (detection limit 1-2 ng) which show superior sensitivity 
and linearity.13  The use of different fluorescent dyes allows multiple samples to be 
pooled and run on the same gel.  This development is called difference gel 
electrophoresis14 and is more reproducible and accurate than traditional 2DE, which 
requires two gel plates.15   
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Protein identification 
Early protein analysis consisted of identifying proteins separated by gels.  Purified 
proteins would be sequenced (either intact or after enzymatic digestion) from the 
amino terminus using Edman degradation.  Systematic sequencing programs 
combined with information from gene sequencing led to the rapid increase in the size 
of sequence databases, and the chance that a particular protein sequence was already 
represented in a protein or gene sequence database also increased.  Thus the 
complete sequence of a protein of interest could be found by database searching, 
without the need for its sequence to be determined de novo.  This was the beginning 
of discovery proteomics. 
 
Although protein sequencing by Edman degradation was reliable and automated, it 
was also slow and had a poor sensitivity,10 so better protein identification techniques 
were needed.  At that time, mass spectrometry had been used for analysing small 
molecules. However, peptides and proteins, like other large molecules, proved 
difficult to ionize under conditions that did not destroy the molecule, and thus were 
unsuitable for mass spectrometry. In the late 1980s, two methods were developed 
that overcame this obstacle and allowed the ionization of peptides and proteins at 
high sensitivity without causing excessive fragmentation. These breakthroughs were 
electrospray ionization (ESI)16 and matrix-assisted laser desorption ionization 
(MALDI).17 The success of these ionization methods in analytical protein chemistry 
led to the development of commercial mass spectrometers equipped with robust ESI 
or MALDI ‘ion source’ instruments, which rapidly penetrated the protein chemistry 
community.   
 
Although MALDI mass spectrometers can determine the mass of a protein or peptide 
with a high degree of accuracy, the intrinsic mass of a protein is not a unique 
identifying feature. It was quickly recognized, however, that the masses of the 
various peptides generated by fragmentation of an isolated protein with an enzyme of 
known cleavage specificity could uniquely identify a protein.  Implementation of this 
discovery in database search algorithms, together with mass spectrometry peptide 
analysis, was used to identify proteins and is called peptide mass fingerprinting.18-22 
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In addition to measuring peptide mass, some of these instruments can isolate specific 
ions from a mixture on the basis of their mass-to-charge (m/z) ratio and fragment 
these ions in the gas phase within the instrument, allowing the recording of MS/MS 
spectra. This fragmentation fingerprint is compared with the theoretical masses of all 
the fragments, which have been obtained from a selected protein database.  This is 
called peptide fragment fingerprinting.23 
 
Because peptide ions fragment in a sequence-dependent manner, the MS/MS 
spectrum of a peptide, in principle, represents its amino acid sequence.  Thus, a 
sequence of a few amino acids can be obtained from an MS/MS spectrum.  This 
amino acid sequence can be used in a classical database search to identify the 
protein. 
 
Biomarkers 
Biomarkers are not new. Laboratory tests, x-rays, electrocardiograms, and other 
established procedures have long been used to demonstrate the presence of disease 
and response to treatment.  Biomarkers may be used to measure disease 
predisposition, to diagnose or stage a disease or to determine its severity, prognosis, 
or outcome.24  Many are familiar to clinicians and have been used for some years 
now.  For example, carcinoembryonic antigen and CA-125 are used to monitor 
cancer,25 haemoglobin A1c is used for monitoring diabetes,
26 and rheumatoid factor is 
used to diagnose and provide a prognosis in rheumatoid arthritis.27  New tools are 
now being applied to biomarker discovery that have developed out of technological 
advances and the growing understanding of molecular biology.  These tools come 
from the fields of genomics, epigenomics, transcriptomics, proteomics, lipidomics, 
and metabolomics.   
 
Biomarkers can be identified using proteomics as follows: plasma or tissue is 
obtained from two populations, one containing the investigated disease and the other 
a suitable control group.  The proteins in each sample (the entire proteome) are 
separated (by a technique such as 2DE) and identified by mass spectrometry. 
Differences in the proteins in the control and diseased populations are sought using a 
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variety of techniques.  Proteins uniquely present in the diseased tissue or condition 
can serve as a diagnostic or prognostic biomarker. 
 
However, there have been many challenges in translating plasma proteomics from 
bench to bedside and relatively few plasma biomarkers have successfully made the 
transition from proteomic discovery to routine clinical use.24 Obstacles to this 
translation include the complexity of the proteome in biologic samples, the presence 
of highly abundant proteins such as albumin in biologic samples that hinder detection 
of less abundant proteins, false-positive associations that occur with analysis of high 
dimensional datasets, and the limited understanding of the effects of growth, 
development, and age on the normal plasma proteome.28 
 
HIV 
The HIV pandemic has resulted in the death of over 25 million people and the virus 
currently infects almost 40 million of the world’s population,29 and Sub-Saharan 
Africa especially South Africa carries the greatest burden of the HIV epidemic.  
Although tremendous progress has been made over the years, understanding of the 
pathogenesis and treatment of the infection is still not optimal.   
 
Currently, quantification of viral RNA levels (viral load) and cluster designation 4 
(CD4) cell count determinations represent the most widely used laboratory assays 
employed in HIV patient management.  Viral load is used by the clinician to measure 
the baseline disease burden prior to initiation of antiretroviral therapy, to assess the 
efficacy of  antiviral drug treatment,  to detect the onset of drug resistance, to predict 
the development of acquired immunodeficiency syndrome (AIDS) -related 
opportunistic infections and to monitor disease progression.30  Clinical data also 
suggest that the viral RNA level at the initial phase of HIV infection (known as the 
set-point) can be used as a prognostic marker for HIV disease progression.31  CD4 
counts are used to decide when to initiate therapy, to monitor the response to therapy, 
and to assess the risk of developing opportunistic infections.32  CD4 counts are 
additionally helpful to evaluate possible treatment failure and to monitor disease 
progression.33  
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However, these tests are not possible in all settings, particularly where resources are 
limited.  They can be prohibitively expensive, are complex to perform, and require 
advanced laboratory infrastructure and highly skilled laboratory technicians.34, 35  
However, inadequate monitoring of HIV progression in adults taking antiviral 
treatment is associated with detrimental outcomes.34, 36, 37  For these reasons, 
alternative ways to monitor HIV have been sought.  These include various serologic 
HIV-1 p24 antigen detection methods,38, 39 a real-time immuno-polymerase chain 
reaction assay that uses HIV-1 p24 antigen as a marker for quantification of 
viraemia,40 qualitative and quantitative cell culture methods, and cheaper methods of 
enumerating CD4 cell numbers.35  The question arises whether there is a role for 
proteomics in increasing our understanding of HIV or in the management of HIV-
infected patients. Conceivably, it may lead to a superior method of monitoring HIV. 
 
HIV Proteomic Research 
Proteomic methods can be applied in various ways to study HIV.  The proteome of 
the virus itself can be analysed.  Cells infected with HIV can be compared to normal 
cells to determine the effect on intracellular proteins.    The cell culture medium of 
cultured HIV-infected cells can be analysed (the secreteome), or plasma can be used 
to assess whole body changes to HIV infection.  The various proteomes can be 
monitored for changes in response to infection or to changes related to treatment.  
The remainder of this review will examine the HIV research performed using 
proteomic methods. In order to illustrate the diverse uses of proteomics, it is grouped 
according to sample type.  The proteome of HIV is continuously being studied and 
comprehensive, up-to-date databases are maintained by the Los Alamos National 
Laboratories (www.hiv.lanl.gov) and by BioAfrica (www.bioafrica.net). 
 
Virions 
Proteomics has been useful in determining the protein structure of HIV virions, 
particularly in determining post-translational modifications and in identifying host 
proteins that become incorporated into the virion – both of which are not obvious 
from genomic information.  2DE and MALDI time-of-flight MS were used to 
analyse the lysate of purified HIV virions.41  Twenty-five proteins inside the virion 
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including a N-terminal formylated isoform of p24gag were identified.  In another 
study42 LC-MS/MS was used to analyse host proteins in the HIV virion, and CD48 
and histones (specifically histones H1, H2, H3, and H4) were discovered to be 
incorporated in the virion. 
 
Macrophage secretions 
HIV-infected and -uninfected macrophages have been cultured and the proteome of 
the media analysed.43  It was shown that matrix metalloproteinase 9 (MMP9) was 
down-regulated in HIV-infected cells and also that this decrease was greatest in cells 
with higher reverse transcriptase activity.  This is significant because MMP9 is a 
well known neurotoxin as shown in cerebrovascular injury, seizures and Alzheimer’s 
disease.44  In a subsequent study,45 six differentially expressed proteins were found. 
These included: cystatin B, cystatin C, L-plastin, leukotrine A4 hydrolase, α-enolase, 
and chitinase 3-like 1 protein (HC-gp39).  The authors noted that these differentially 
expressed proteins represented a wide range of functional groups and include 
structural (cytoskeleton) proteins, proteins involved in redox reactions, regulatory 
proteins and enzymes.   They also reported that following HIV infection, the 
macrophage is stimulated and the number of secreted proteins increased. This 
observation supports the notion that the virus accelerates production and secretion of 
macrophage proteins to its advantage. 
Cerebrospinal fluid 
Approximately half of HIV-infected individuals develop some form of HIV-
associated neurocognitive disorder (HAND), which is comprised of  HIV-associated 
dementia (HAD), mild neurocognitive disorder, and asymptomatic neurocognitive 
impairment.46 Currently, the diagnosis of HAND is a diagnosis of exclusion made 
primarily on clinical grounds requiring the elimination of concurrent opportunistic 
infections, psychiatric disorders and malignancies.  In order to aid with diagnosis, 
much has been expended to find a biomarker to support the diagnosis of HAND.   
Cerebrospinal fluid (CSF) has been analysed from HIV-positive individuals with and 
without HAD.47  Twenty differentially expressed proteins were identified, six of 
which (vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen 
C-endopeptidase enhancer 1 and cystatin C) were validated by Western blot 
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analyses.  In another study 48 searching for biomarkers of HAND in CSF, nine 
proteins unique to HIV cognitive impairment were identified, including soluble 
superoxide dismutase, migration inhibitory factor - related protein 14, macrophage 
capping protein, neurosecretory protein VGF, galectin-7, L-plastin, acylphosphatase 
1, and a tyrosine 3/tryptophan 5-monooxygenase activation protein.  Further work is 
required in order to establish which protein or combination of proteins will make an 
ideal biomarker of HAND. 
 
Serum or plasma 
The plasma from subjects with the AIDS has been compared to that from  healthy 
individuals.49   The expression of seven proteins was found to be increased (alpha-1-
antichymotrypsin, antitrypsin, ALB protein, haptoglobin beta chain, immunoglobulin 
light chain, haptoglobin alpha-2 chain, and transthyretin) whilst one (apolipoprotein 
A-I) was decreased. Furthermore, a change of expression of the various isoforms of 
apolipoprotein A-I was observed.  The authors hypothesised that this may be used to 
monitor the progress of HIV infection. Serum has also been used to search for 
biomarkers of HAND.50  Immunodepleted serum samples from patients with and 
without HAD were compared and it was discovered that gelsolin and prealbumin 
were differentially expressed in these patient groups. 
 
Brain microvascular endothelial cells 
The blood-brain-barrier dysfunction in HIV infection has also been investigated 
directly.51   Brain microvascular endothelial cells were co-cultured with HIV-infected 
and -uninfected monocyte-derived macrophages.  The endothelial cells were lysed 
and the lysate was subjected to two-dimensional difference gel electrophoresis.  
Structural, cytoskeletal, regulatory, metabolic, voltage-gated ion channels, heat 
shock, transport and calcium binding proteins were shown to be significantly 
upregulated in endothelial cells due to interactions with HIV- infected macrophages.  
These studies provided proof that HIV-infected macrophages affect the endothelial 
cells and can, in this way, affect blood-brain-barrier dysfunction and the 
development of HIV central nervous system disease. 
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T-cells 
Since T-cells play such a crucial role in the pathogenesis of HIV, it is logical to study 
their proteome.  In a study that focussed specifically on plasma membrane-associated 
proteins on a chronically HIV-infected T-cell line (ACH2), 17 differentially 
expressed proteins were discovered.52  The majority of the identified proteins (65%) 
were integral membrane or membrane-associated proteins that could be divided into 
two functional categories – proteins involved with cell adhesion, structure, and 
migration, and receptors and receptor-associated proteins.  The receptor and 
receptor-associated proteins were involved in the regulation of cell death and 
survival and included X-linked inhibitor of apoptosis. This protein was increased, 
and it may be that up-regulation of this anti-apoptotic protein is a mechanism to 
increase cell survival to counterbalance the apoptotic effects of some viral accessory 
proteins. 
 
The lipid metabolism-altering effects of both HIV and HIV therapy have been well 
documented.53  A T-cell line (RH9) was studied before and after HIV infection to 
investigate if the T-cells showed  alteration in the production of any proteins 
involved in lipid metabolism.54  After HIV infection, 18 proteins were differentially 
expressed, 12 of which were exclusively expressed in HIV-infected cells.  Seven 
proteins belonged to various families of enzymes/kinases (complement C3 peptidase, 
phosphatidylinositol-4-phosphate 3-kinase C2 domain containing beta polypeptide, 
fatty acid synthase, glutathione peroxidase-1, protein kinase C beta, long chain-fatty-
acid-CoA ligase 1, epidermal fatty acid binding protein); five were transporter 
proteins, two were transmembrane receptors, two were molecular chaperones and 
there was one each of the ligand-binding and adapter-like proteins.  The low-density 
lipoprotein receptor 1 and the very low-density lipoprotein receptors were found to 
be upregulated after HIV infection.  Among all the differentially regulated proteins, 
apolipoprotein-B100 showed the greatest increase post- HIV infection.  
Apolipoprotein-A-I was shown to be synthesised in HIV-infected but not in 
uninfected cells.  It was concluded that the replication of HIV in human T-cells alone 
alters the synthesis of novel enzymes, kinases and other proteins that enhance fatty 
acid synthesis, increase lipid peroxidation (crystallization), disrupts lipid metabolism 
and reduces lipid clearance without any influence of genetic or epigenetic factors. 
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Presumably, these changes in lipid metabolism may also occur in other cell types and 
may potentially contribute to the dyslipidaemia observed in many patients with HIV 
infection. 
 
Cervical lavage samples 
A group of Kenyan sex workers has been shown to be relatively resistant to HIV.55  
It has been suggested that the mucosal layer in the cervicovaginal compartment may 
play a role in mediating this resistance. In order to study this further, cervical lavage 
specimens from ∆-32-CCR5-negative and HIV-negative (resistant) sex workers were 
compared to various controls.56  Comparison of protein profiles revealed that a group 
of antiproteases was upregulated in HIV-1-resistant women.  These included those 
from the serpin B family (B1, 3, 4, and 13), alpha-2 macroglobulin-like 1, and 
cystatin A, all of which have antiprotease or anti-inflammatory properties.  It is 
possible that overexpression of these proteins confers protection by maintaining the 
integrity of the epithelial barrier. 
 
Conclusion 
Since its first discovery in the early 1980’s almost 65 million people have been 
infected with HIV.  Significant strides have been made since in our understanding of 
the pathogenesis and treatment of HIV infection, but currently available monitoring 
and treatment options are far from ideal.  Since HIV monitoring has been shown to 
be essential when treating patients, cheaper and simpler markers of HIV infection are 
necessary.  Proteomics has provided a new tool for researching HIV and has made 
some significant contributions.  One of these is the discovery and identification of 
potential biomarkers for HAND, both in CSF and serum.  Hopefully, this approach 
can be applied to the HIV infection itself.   Ideally, it will lead to the classification of 
proteins involved in the progression of HIV and allow the development of new 
biomarkers for HIV. 
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Serum Proteome Changes Following HIV Infection 
 
 
Synopsis 
 
 
 
 
 
 
 
The aim of this study was to develop additional biomarkers for human 
immunodeficiency viral infection.  Two-dimensional gel electrophoresis and 
MALDI-TOF mass spectrometry were used to compare the serum proteome of HIV-
positive subjects to HIV-negative subjects. Eleven protein spots were identified as 
being significantly different between the two groups.  Nine spots were significantly 
decreased and two spots were significantly increased in the HIV-positive group 
compared to the HIV-negative group.  
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Abstract  
The aim of this study was to compare the serum proteome of stage I HIV-positive 
subjects to HIV-negative controls in order to identify novel protein changes that are 
induced in the human serum proteome following HIV infection.  Samples were 
separated into HIV-positive and HIV-negative groups, and subjected to two-
dimensional gel electrophoresis. The gels were silver-stained and analysed to detect 
significant differences between protein spots.  Significant spots were digested by 
trypsin and subjected to analysis using MALDI-TOF mass spectrometry.  Eleven 
spots were found to be significantly different between the two groups. Nine spots 
were significantly decreased and two spots were significantly increased in the HIV-
positive group compared to the HIV-negative group. The proteins found to be 
decreased were identified as abnormal spindle-like microcephaly-associated protein, 
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type II cytoskeletal keratin, alpha-1-acid glycoprotein, 60S ribosomal protein L4, 
haptoglobin, apolipoprotein A-I, zinc finger CCCH domain-containing protein 13 
and haemoglobin beta chain. The proteins found to be increased were identified as 
coiled-coil domain-containing protein 49 and 60S ribosomal protein L4.  This 
information could be used to develop immunoassays to analyse protein changes in 
the clinical laboratory as an additional method of monitoring changes in HIV 
infection. 
 
Keywords 
HIV • Biomarker • Proteomics 
 
Introduction 
The Human Immunodeficiency Virus (HIV) pandemic has resulted in the death of 
over 25 million people and the virus currently infects almost 40 million of the 
world’s population.1  Although tremendous progress has been made over the years in 
the monitoring and treatment of HIV, the management of this disease is still not 
optimal.   
 
Currently, quantification of viral RNA levels (viral load) and cluster designation 4 
(CD4) cell count determinations are the most widely used laboratory assays 
employed in monitoring HIV patients.  Viral load is used by the clinician to measure 
the baseline disease burden prior to initiation of antiretroviral therapy, to assess the 
efficacy of  antiviral drug treatment,  to detect the onset of drug resistance, to predict 
the development of acquired immunodeficiency syndrome (AIDS) -related 
opportunistic infections and to monitor disease progression.2  CD4 counts are used to 
decide when to initiate therapy, to monitor the response to therapy, and to assess the 
risk of developing opportunistic infections.3  CD4 counts are additionally helpful to 
evaluate possible treatment failure and to monitor disease progression.4  
 
However, these tests are not possible in all settings, particularly where resources are 
limited.  They can be prohibitively expensive, are complex to perform, and require 
advanced laboratory infrastructure and highly skilled laboratory technicians.5, 6  
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However, inadequate monitoring of HIV progression in individuals taking antiviral  
treatment is associated with detrimental outcomes.5, 7, 8  For these reasons, alternative 
ways to monitor the progress of HIV have been sought.6, 9-11   
 
Human plasma or serum is potentially the single most informative sample that can be 
obtained from an individual that describes their current state of health.  It is the 
primary clinic specimen, easy to collect and potentially contains proteins from every 
tissue in the body.12, 13  Plasma proteins have proven very useful for diagnostic, 
prognostic, and therapeutic development. With proteomic tools recently established, 
profiling of the human plasma proteome has become easier in the quest for disease-
related markers.13  Researchers have looked to serum to find potential biomarkers for 
hepatitis B, hepatitis C, and human T-cell leukaemia virus14 among other diseases, 
and serum has been used in HIV-positive patients to find biomarkers for HIV-
associated neurocognitive disorders.15 
 
In view of the success of the above studies, the aim of this study was to search for 
biomarkers of HIV infection in serum.  This was achieved by comparing the serum 
proteome of asymptomatic HIV-positive and HIV-negative subjects using two-
dimensional gel (2D-gel) electrophoresis profiles.  Proteins were identified using 
peptide mass fingerprinting generated by matrix-assisted laser desorption ionization 
time of flight (MALDI-TOF) mass spectrometry (MS).  
 
Materials and Methods 
Study Population.  The study was performed with ethics approval from the 
Research Ethics Committee of the Health Sciences Faculty of the University of Cape 
Town (REC REF 211/2007).  All subjects were enrolled at the Masiphumelele 
primary health clinic.  Only Xhosa males between 21 and 35 years of age were 
admitted to the study.  All subjects who agreed to participate signed a consent form 
and completed a questionnaire regarding their health.    The health questionnaire was 
used to ensure only asymptomatic subjects (World Health Organization Clinical 
Stage I)16 were selected and that there were no comorbid conditions.  It also ruled out 
any subject who was taking any form of medication which may complicate the 
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analysis. A copy of the health questionnaire is available in the supporting 
documentation. 
HIV Testing.  HIV testing was performed on site at the clinic.  All subjects were 
counselled before testing.  Testing was performed on a finger-prick sample using a 
First Response HIV Card Test (PMC Medical Pvt Ltd).  If this test was positive, 
repeat testing was performed on a HIV-1/2 Triline Card Test (Pareekshak).  Both 
these tests are immuno-chromatographic assays sensitive to antibodies against HIV-1 
antigens (gp120, gp41 and p24) and an HIV-2 antigen (gp36). 
Sample Collection and Storage.  Blood was collected from the left cubital fossa 
of subjects into BD Vacutainer SST II Advance tubes.  The blood was spun at 4000 g 
for 5 min to separate the serum.  An aliquot of the serum was taken for biochemical 
testing. The remaining serum was frozen and stored at -70ºC until 2D-gel 
electrophoresis could be performed.  All samples were fully processed within 6 h. 
Serum Biochemistry.  Creatinine, alanine transaminase (ALT), C-reactive 
protein (CRP) and glucose were measured immediately upon arrival at the laboratory 
on a Roche/Hitachi modular analyser.  Samples with creatinine values greater than 
120 µM, glucose greater than 7.0 mM, ALT greater than 40 U/L or CRP greater than 
5.0 mg/L were excluded from further analysis. 
Sample Preparation.  Albumin and immunoglobulin G (IgG) were removed 
from 10 µL of each sample using an albumin/IgG Removal Kit (ProteoSeek).  The 
samples were diluted and mixed with immobilised Cibacron Blue/Protein A gel 
slurry as directed by the package insert.  20 µL of the albumin/IgG-free filtrate was 
then dissolved in 130 µL of rehydration buffer (8 mM urea, 4% CHAPS, 0.0002% 
bromophenol blue, 50 mM dithiothreitol (DTT), 0.5% ampholyte solution). 
Isoelectric Focusing.  Immobilised pH gradient (IPG) strips (Bio-Rad 7cm pH 3-
10 ReadyStrips) were left overnight to rehydrate in 125 µL of the sample/rehydration 
buffer covered with mineral oil.  Isoelectric focusing (IEF) was performed at 
increasing voltages cumulating at 10 000 V with over 15 000 Vh of potential time.  
After completion of the IEF, the strips were washed for 15 min in 5 mL of 
equilibration buffer (50 mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 2% sodium 
dodecyl sulfate (SDS), 0.0002% bromophenol blue) with 50 mg of DTT.  The strips 
were then washed for a second time for 15 min in 5 mL of equilibration buffer with 
125 mg of iodoacetamide.  A final third wash was performed for 15 min using plain 
equilibrium buffer. 
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Polyacrylamide Gel Electrophoresis.  A 10% polyacrylamide gel (375 mM Tris-
HCl, 10% acrylamide/bisacrylamide, 0.1% SDS, 0.05% ammonium persulfate and 
0.0005% tetramethylethylenediamine) was prepared.  The IPG strip was placed along 
the top of the polyacrylamide gel and covered with 2% agarose gel.  Electrophoresis 
took place at 60 mA for 1 h.  The gels were fixed overnight in a solution containing 
10% acetic acid and 40% ethanol.   
Silver Staining.  The gels were washed in a 30% ethanol solution for 20 min and 
then in distilled water for 20 min, after which they were sensitized in a 0.02% 
sodium thiosulphate solution for 1 min.  The gels were washed again in water and 
then left in a silver stain solution (0.2% silver nitrate, 0.074% formaldehyde) for 20 
min.  A fourth wash with water was performed, after which the gels were put into 
developer solution (3% sodium carbonate, 1.85% formaldehyde, 0.0005% sodium 
thiosulfate) for 5 min.  After a final wash, the process was stopped with a 0.5% 
glycine solution. 
Gel Analysis.  Gels were analysed with 2D-gel analysis software (Melanie 
version 7.03).  The following parameters were used to detect spots on the gel:  
smoothness: 2, saliency: 50, min area 5. Spot differences were considered significant 
if the mean ratio between the HIV-positive and HIV-negative groups was greater 
than two or less than a half, and the p value was less than 5% as calculated using 
Melanie’s built-in ANOVA calculator.  All spots considered significant were 
manually checked to ensure correct matching. 
Protein Extraction.  Protein analysis was performed at the Centre for Proteomic 
and Genomic Research (Institute of Infectious Diseases and Molecular Medicine, 
Faculty of Health Sciences, University of Cape Town).  Gel slices supplied were cut 
up into 1 mm × 1 mm × 2 mm pieces and destained in Eppendorf 1.5 mL tubes with 
200 mM NH4HCO3:acetonitrile 50:50 (Romill; Sigma) until clear. Samples were 
dehydrated and desiccated before reduction with 5 mM triscarboxyethyl phosphine 
(TCEP; Fluka) in 100mM NH4HCO3 for 30 min at 56 °C. Excess TCEP was 
removed and the gel pieces again dehydrated. Cysteine groups were 
carbamidomethylated with 100 mM iodoacetamide (Sigma) in 100 mM NH4HCO3 
for 30 min at room temperature in the dark. After carbamidomethylation the gel 
pieces were dehydrated and washed with 50 mM NH4HCO3 followed by another 
dehydration step. Proteins were digested by rehydrating the gel pieces in trypsin 
(Promega) solution (20 mg/L) and incubating at 37 °C overnight. Peptides were 
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extracted from the gel pieces with 50 µL 0.1% trifluoroacetic acid (TFA) (Sigma). 
The samples were dried down and 50 µL of water was added and concentrated to less 
than 20 µL to remove residual NH4HCO3.  The extracted peptides were concentrated 
on a C18 ZipTip® and eluted directly onto the MALDI source plate with cyano-4-
hydroxycinmamic acid (Fluka), 5 g/L matrix in 66% acetonitrile, 0.1% TFA, 10 mM 
NH4H2PO4 (Fluka).  
Mass Spectrometry.  Mass spectrometry was performed with a 4800 MALDI 
TOF/TOF (Applied Biosystems). All MS spectra were recorded in positive reflector 
mode. Spectra were generated with 500 laser shots/spectrum at laser intensity of 
4000 (arbitrary units) with a grid voltage of 16 kV. All peptide-containing spots were 
internally calibrated using trypsin autolytic fragments.  
Database Analysis.  Database interrogation was performed with the Mascot 
algorithm using the MSDB, Swissprot and NCBI databases on a GPS workstation. 
Search parameters were as follows: Species – Homo sapiens, Enzyme – trypsin; 
Maximum number of missed cleavages -1;  Fixed modifications – carbamidomethyl 
(C);  Variable modifications oxidation (M); N-terminal carbamyl; K-carbamyl; N-
terminal and K-carbamyl , precursor tolerance - 100 ppm, fragment tolerance – 0.2 
da. 
 
Results 
Subjects.  Twenty HIV-positive subjects and 31 HIV-negative subjects met the 
clinical and demographic criteria and agreed to participate in this study.  They all 
signed the consent form and filled in the given health questionnaire.  Only 23 of the 
HIV-positive samples and 13 of the HIV-negative samples met the biochemical 
inclusion criteria of the study and only these samples were used for further analysis. 
2D-Gel Analysis.  2D-gels were prepared as explained.  Thirteen gels were run 
from each group.  Only six from the HIV-negative group and eight gels from the 
HIV-positive group were of sufficient quality for analysis.  7 659 spots were detected 
in the 14 gels and 562 matches were made.  Eleven spots were found to be 
significantly different in the two groups.  One spot (386) was only present on the 
HIV-positive gels.  Three spots (418, 439, 482) were present only on the HIV-
negative gels.  Seven spots (44, 59, 92, 104, 116, 218, 220) were present on both 
gels, and all except one (104) were found to be down-regulated in HIV-positive 
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subjects compared to HIV-negative subjects.  Figure 1 shows a representative gel 
from each group with the relevant spots labelled.  Details of each significant spot are 
given in Table 1. 
Protein Identification by MS.  The analysis of the samples submitted showed 
that spectra of suitable quality were obtained for the analysis. A bovine serum 
albumin control digest indicated that the digestion process was successful with the 
high concentration but the lower concentration could not be identified with all the 
databases used. The blank gel control showed only the expected trypsin and matrix 
crystals.  A non-redundant database search was performed which allowed all the 
samples to be identified with high confidence.  Full results are shown in Table 2.  
 
Discussion 
The aim of this study was to compare the serum proteome of HIV-positive and HIV-
negative subjects.  We were able to identify eleven differentially expressed proteins, 
all fulfilling diverse functions in different tissues.  Three of these proteins are well 
known plasma proteins: α1-acid glycoprotein (A1AG), haptoglobin and 
apolipoprotein A-1 (ApoAI).  Two proteins form part of the cytoskeleton:  type II 
cytoskeletal keratin 1 (T2CK1) and abnormal spindle-like microcephaly-associated 
protein (ASMP).  One protein is found exclusively in erythrocytes (haemoglobin beta 
chain), one protein is involved with protein synthesis (60S ribosomal protein L4), 
and the other two identified proteins are intracellular proteins with, as yet, uncertain 
roles (coiled-coil domain-containing protein 49 and zinc finger CCCH domain-
containing protein 13).  Several of these proteins have been reported previously to 
vary with HIV, while with others, this is the first such report. 
 
A1AG, ApoAI and haptoglobin are acute-phase proteins.  An acute-phase protein is 
defined as a plasma protein whose concentration increases (positive acute-phase 
proteins) or decreases (negative acute-phase proteins) by at least 50% during an 
inflammatory reaction.17  They have been well studied previously as a means to 
monitor HIV infection.  Haptoglobin, CRP and A1AG have been found to increase in 
HIV-positive patients as the CD4 count falls, while ApoAI levels have been found to 
decrease.18-21  Elevated levels of acute-phase proteins can also be found in 
asymptomatic HIV-positive patients.  Samples with an elevated CRP were excluded 
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from our analysis to help ensure only Stage I disease was studied.  Yet, despite a 
normal CRP, changes in other acute-phase proteins were detected.  This discordance 
between the plasma concentrations of different acute-phase proteins is not 
uncommon. This is because the components of the acute-phase response are 
individually regulated.22 
 
A1AG and haptoglobin play a greater role than simply markers of inflammation.  
Haptoglobin is a haemoglobin-binding protein that occurs in three common 
phenotypes: Hp1-1, Hp2-2 and the heterozygous Hp2-1.23  Viral loads have been 
found to be significantly higher in Hp2-2 individuals than in Hp1-1 controls,24 and 
CD4 counts have been found to be significantly lower.25  Haptoglobin has also been 
reported to be one of the first acute-phase proteins to rise during HIV infection.20  
A1AG, also called orosomucoid, is a small glycoprotein whose physiologic role is 
still unclear.  It is thought to function mainly as a carrier protein for basic and neutral 
lipophilic endogenous compounds or xenobiotics.  Two A1AG proteins are encoded 
for (ORM1 and ORM2) with slightly different drug-binding properties.26, 27 A1AG 
has been found to bind to both the HIV envelope and to macrophage chemokine 
receptor CCR5, a major co-receptor for HIV, and thus may play a role in the 
pathogenesis of HIV.28, 29  A1AG levels are known to be 50-60% higher in HIV-
infected people than non-infected controls.30  It is quite promising that these two 
proteins, having known HIV associations, were detected as being significantly 
different.  What is unexplained, is that these proteins were found to be decreased in 
HIV-positive samples compared to controls, as most other studies have found higher 
levels in HIV-positive people. 
 
Lipid abnormalities are well-known to occur in HIV infection.  HIV dyslipidaemia is 
characterised mainly by decreased plasma concentrations of total, low-density 
lipoprotein, and high-density lipoprotein cholesterol, and elevated levels of plasma 
triacylglycerides.31, 32  In our study, ApoAI was found to be down-regulated in HIV-
positive patients.  This result is in keeping with the results of a previous study that 
compared the proteome of patients with AIDS to HIV-negative controls.33  In that 
study, it was found that ApoAI was down-regulated in AIDS and this was validated 
by both Western blot analysis and real time polymerase chain reaction on ApoAI 
mRNA. In another study, ApoAI was shown to correlate with CD4 count.34  ApoAI 
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and HDL cholesterol also return to their pre-disease values with antiviral 
treatment.34, 35 Based on our study and this finding, ApoAI is a candidate biomarker 
for HIV. 
 
ASMP is an intracellular cytoskeletal protein that is predicted to be involved in 
mitotic spindle function during mitosis.36  Homozygous mutations of the ASMP gene 
are the most common cause of autosomal recessive primary microcephaly.37  
Although there has been no reported association between HIV and ASMP, it is 
interesting to note that Hepatitis C virus has been shown to down-regulate the 
expression of ASPM,38 and ASPM is a biomarker for hepatocellular carcinoma.39  
This protein was identified in three different spots in the gel.  ASPM is known to 
occur as various splice variants and isoforms, and to bind a range of cytoskeletal 
proteins.36  This may explain its occurrence in multiple positions in the gel, but more 
detailed structural analysis is required in order to resolve this issue. 
 
The two upregulated proteins were 60S ribosomal protein L4 and coiled-coil domain-
containing protein 49.  Very little literature is available on these two proteins and this 
is the first report of  a possible relationship with HIV.  Another novel potential 
marker discovered was zinc finger CCCH domain-containing protein 13.  Again, 
very little literature is available on this protein, and there are no previous reports 
regarding an association with HIV.  Further research is required on the role of these 
three proteins in health and disease.  
 
T2CK1 is a basic protein which is specifically expressed in the spinous and granular 
layers of the epidermis.  T2CK1 forms half of a heterodimer that assembles into 
intermediate filaments, thereby imparting mechanical strength to the keratinocytes.40  
Mutations in the gene encoding T2CK1 are responsible for a diverse group of 
disorders of keratinisation.41  Although some researchers have investigated keratin 
expression in HIV,42, 43 there are no reports of its use as a potential biomarker.  
However, the abundance of keratin in the skin makes it a likely contaminant both 
through venipuncture and elsewhere. 
 
Haemoglobin beta chain levels were found to be decreased in HIV-positive subjects 
compared to HIV-negative subjects.  Haemoglobin has previously been used as a 
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biomarker for HIV.  Haemoglobin levels have been shown to fall with CD4 count,44 
and a low haemoglobin level  is predictive of death in patients starting antiviral 
treatment.  Haemoglobin levels also rise after commencing antiviral treatment.45  Not 
surprisingly, all the previous studies have looked at whole blood haemoglobin and 
not serum haemoglobin.  If serum haemoglobin is a reflection of whole blood 
haemoglobin (when no haemolytic disease is present) then our results could concur 
with the other studies.   Although no haemolysed samples were used in our study, its 
high concentration in erythrocytes could make it an easy contaminant. 
 
Conclusion 
The biomarker development process consists of four stages:  discovery, validation, 
qualification and implementation.46  In this study, we have used proteomic methods 
to complete the discovery phase of biomarker development in early HIV.  We have 
successfully identified a number of candidate proteins which undergo consistent 
changes in HIV disease, some of which have already been studied as potential HIV 
biomarkers.  The fact that four previously known markers were detected gives 
credence to our method and provides some validation of our study.  We have 
identified five novel proteins, which have not previously been described to have roles 
as HIV biomarkers.  Although rigorous validation is necessary, this information 
could be used to develop immunoassays to analyse protein changes as an additional 
method of monitoring changes in HIV infection in the clinical laboratory. 
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Tables 
 
 
Table1.  List of differentially expressed proteins 
Spot number N (%Vol) P (%Vol) Ratio (N/P) p value 
44 0.661 0.336 1.968 0.022 
59 0.091 0.017 5.336 0.032 
92 0.239 0.056 4.235 0.011 
104 0.148 0.357 0.416 6.32×10-4 
116 0.723 0.206 3.518 0.003 
218 0.201 0.044 4.576 0.045 
220 1.210 0.382 3.171 0.007 
386 - 0.232 0 0.012 
418 0.132 - - 2.34×10-5 
439 0.372 - - 4.17×10-4 
482 0.121 - - 0.007 
N – HIV-negative group; P – HIV-positive group 
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Table 2.  Identification of differentially expressed spots 
Spot 
number 
Protein NCBI* MSDB* 
Protein 
score 
44 
Abnormal spindle-like 
microcephaly-associated protein 
55663315 AAN40011 134 
59 Keratin, type II cytoskeletal 1 7331218 AAF60327 67 
92 
Abnormal spindle-like 
microcephaly-associated protein 
24061713 AAM44119 146 
104 
Coiled-coil domain-containing 
protein 49 
8923271 Q9NXE8 125 
116 Alpha-1-acid glycoprotein 2 29170378 OMHU2 138 
218 
Abnormal spindle-like 
microcephaly-associated protein 
55663315 AAN40011 114 
220 Haptoglobin 758071 HPHU1 149 
386 60S ribosomal protein L4 22002063 T09551 95 
418 
Zinc finger CCCH domain-
containing protein 13 
122889118 Q8NDT6 63 
439 Apolipoprotein A-I 178775 CAA00975 123 
482 Haemoglobin subunit beta 56749856 AAD19696 111 
*Accession numbers 
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Figures 
Figure 1.  Representative 2D-gels from each group 
(Caption on next page) 
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Figure 1. Representative 2D-gels from each group 
Sample gels from HIV-negative (top) and HIV-positive (bottom) groups with 
significant spots labelled. 
Increased in HIV-positive group: 104 - Coiled-coil domain-containing protein 49, 
386 - 60S ribosomal protein L4. 
Decreased in HIV-positive group: 44, 92, 218 – ASMP, 59 – T2CK1, 116 – A1AG, 
220 - Haptoglobin, 439 - ApoAI, 418 - Zinc finger CCCH domain-containing protein 
13, 482 - Haemoglobin subunit beta. 
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Supporting Information 
 
Health Questionnaire 
 
DEPARTMENT OF CHEMICAL PATHOLOGY 
UNIVERSITY OF CAPE TOWN 
 
HEALTH QUESTIONNAIRE 
 
BIOMARKER DISCOVERY IN HIV/AIDS USING PROTEOMICS 
 
 
Visit date: ______________________ 
 
This study is only open to Xhosa males between 21 and 35 years of age. 
 
Questions 
1. Are you on any prescription medication? 
2. Have you ever been diagnosed with: 
a. Diabetes? 
b. TB? 
c. Asthma? 
d. High blood pressure? 
e. Jaundice? 
f. Epilepsy? 
3. Have you had an operation in the last 12 months? 
4. Do you suffer from shortness of breath while walking? 
5. Do you wake up during the night with difficulty in breathing? 
6. In the last three months: 
a. Have you had a cough? 
b. Have you had diarrhoea? 
c. Have you had any pain with urination? 
7. Have you ever coughed up blood? 
8. Have you been losing weight recently (without trying)? 
9. Are you currently suffering from fever, chills or night sweats? 
10. Do you have any skin or mouth sores that will not heal? 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   55 
 
If you have answered YES to any of the above questions, then you are unfortunately 
NOT suitable for the study. 
 
 
Thank you for participating in this study! 
 
 
Phlebotomy done: _______________  ________________  _______________ 
  Date    Time  Signature 
 
 
Bloods collected: ______________  ________________  _______________ 
  Date    Time  Signature 
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Journal of Proteome Research: Instructions to 
Authors 
 
The text below includes the table of contents and the section entitled Preparation of 
Manuscripts from the Instructions to Authors document released by the Journal of 
Proteomic Research.  The full text can be downloaded at: 
http://pubs.acs.org/paragonplus/submission/jprobs/jprobs_authguide.pdf 
 
 
Instruction to Authors 
(Revised January 2010) 
 
 
Contents 
(1) Publication – JAMs publication – ASAP publication – Answers to Questions/Requests 
from Authors after Publication – Addition and corrections – ASC policies for e-
prints and reprints – Page charge 
(2) Web Submission – Original and Revised Manuscripts – Manuscript Preparation & 
Content – Paragon Plus content – Author and co-author information – Peer review – 
Copyright – Cover letter – Request for change after submission – Revised 
manuscripts 
(3) Preparation of Manuscripts – General guidelines for manuscript preparation – 
Elements of a Manuscript – Title and author list – Abstract – Keywords – Table of 
contents synopsis instructions – Manuscript contents – Introduction – Experimental 
section – Conclusions – Tables – References – Nomenclature – Artwork – 
Supporting Information – Manuscript types – File preparation for manuscript 
revisions –Acceptable word-processing packages 
(4) Galley Approval Process – Proofs 
(5) Updated Instructions 
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The Journal of Proteome Research invites contributions of original research in all 
aspects of global protein analysis and function. The research should emphasize 
synergy between physical and life sciences that results in a multidisciplinary 
approach to the understanding of biological processes. In the selection of 
manuscripts for publication, the Editors place emphasis on the quality and originality 
of the work as well as on the breadth of interest to readers and subscribers. 
 
Manuscripts can be submitted as Articles, Letters, Perspectives, Technical Notes, 
Tutorials, Rapid Communications, and Reviews. Reviews are to be comprehensive, 
critical accounts of work in a given area. 
 
Authors and reviewers are encouraged to consider the guidelines governing the 
analysis and documentation of peptide and protein identifications, which were 
drafted during the Paris workshop on proteomics standards in May 2005. To access 
these guidelines, go to the Journal of Proteome Research homepage. Click 
Submission & Review, then Information for Authors, then Proteomics Guidelines. 
 
 (3) Preparation of Manuscripts 
 
General guidelines for manuscript preparation 
The Journal of Proteome Research encourages author(s) to prepare manuscripts 
using the template available on the web. If the template is not used, manuscripts must 
be prepared with a word processor and be double-spaced. All pages must be 
numbered. Author(s) should consult The ACS Style Guide, 3rd ed. (ACS: 
Washington, DC, 2006) for guidance in preparing their manuscripts. The ACS Style 
Guide is available from Oxford University Press, Order Department, 201 Evans Rd., 
Cary, NC 27513. Author(s) who are not fully fluent in idiomatic English are urged to 
obtain assistance to correct errors in English grammar, usage, and style. Deficiencies 
in these areas hinder the scientific review process and may substantially delay or 
prevent acceptance of a manuscript. 
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Elements of a Manuscript 
Title and author list 
Titles should clearly and concisely reflect the emphasis and content of the paper. 
Titles are of great importance for current awareness and information retrieval and 
should be carefully constructed for these purposes. Be consistent in author 
designation; supply first name, middle initial, and last name for complete 
identification. At least one author must be designated with an asterisk as the author to 
whom correspondence should be addressed; telephone and fax numbers and an email 
address must be listed for the corresponding author. All other authors are encouraged 
to supply contact information. 
All authors’ names that are listed must be the same as what is listed on the Paragon 
Plus submission page; i.e., all authors’ names must be entered into the webpage also. 
With very few exceptions, request for changes or additions of authors will not be 
approved after acceptance of the manuscript by the Editor. 
 
Abstract 
All manuscripts must contain an abstract (200 words maximum) that should state 
briefly the purpose of the research, principal results, and major conclusions. 
 
Keywords 
Please include keywords to help categorize the manuscript. Author(s) should supply 
no more than 10 keywords per manuscript. 
 
Table of contents synopsis instructions 
The Journal of Proteome Research features a Table of Contents (TOC) Synopsis that 
contains a graphic presentation and synopsis for each entry, in addition to the title 
and author list. Author(s) are required to submit a synopsis (70 words maximum) 
describing the salient features of the research accompanied by an informative 
diagram or illustration. The use of colour to enhance the quality and appearance of 
the graphic is strongly encouraged. Synopsis artwork should be no wider than 9.0 
cm and no taller than 5.0 cm. The graphic file will be reproduced at 100% of the 
submission size and should be saved as a TIFF at 300 dpi for colour and at 1200 dpi 
for black and white. A surrounding margin will be added to this width and height 
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during production. The TOC graphic and synopsis should be appended as the last 
page of the word-processing file that is submitted online. 
 
Manuscript contents 
All sections of a paper must be presented in a clear and concise manner. Indicate the 
breakdown among and within sections with centre heads and side heads. Results and 
Discussion follow the Experimental Section. Keep all information pertinent to a 
particular section and avoid repetition. 
 
Introduction 
The introduction should state the purpose of the investigation and should include 
appropriate citations of relevant, precedent work but should not include an extensive 
review of marginally related literature. If the manuscript describes a new or 
improved method, a clear comparison with existing methods must be provided 
(including appropriate literature citations). 
 
Experimental section 
Use complete sentences (i.e., do not use outline form). Be consistent in voice and 
tense. Apparatus: List only devices of a specialized nature. Reagents: List and 
describe preparation of special reagents only. Do not list reagents normally found in 
the laboratory or preparations described in standard handbooks and texts. 
Procedures: Because procedures are intended as instructions to permit work to be 
repeated by others, give adequate details of critical steps. Published procedures 
should be cited but not described, except where the presentation involves substantial 
modifications. Very detailed procedures should be presented in a Supporting 
Information section. Safety considerations: Describe in detail all safety 
considerations, including procedures that are hazardous or require special 
precautions and reagents that are toxic, so that laboratory workers who repeat 
the experiments can take appropriate safety measures. Include procedures and 
references for the neutralization, deactivation, and ultimate disposal of unusual 
byproducts. Results and Discussion: The results may be presented in tables or 
figures; however, many simple findings can be described directly in the text with no 
need for tables or figures. The discussion should be concise and present an 
interpretation of the results. In most cases, combining results and discussion in a 
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single section will give a clearer, more compact presentation. Test subjects: It is the 
responsibility of the author(s) to obtain appropriate institutional approval for the use 
and generation of data from animal and human samples. 
 
Conclusions 
Use the conclusion section only for interpretation and not to summarize information 
already presented in the text or abstract. 
 
Tables 
Tables should be numbered consecutively with Arabic numerals and should be 
grouped at the end of the paper. Each table should be provided with a descriptive 
heading, which, together with the individual column headings, should make the table 
as self-explanatory as possible. Footnotes in tables should be cited in the table by 
italic superscript letters. The sequence of letters should proceed by line rather than by 
column. If a reference is cited both in the text and in a table, insert a lettered footnote 
in the table to refer to the numbered footnote in the text. When formatting a table, 
author(s) are requested to keep in mind the type area of the journal page (17.8 × 25.0 
cm) and the column width (8.5 cm) and to make tables conform to the limitations of 
these dimensions. When data are arranged into columns, space should be used 
efficiently. 
 
References 
Number literature citations and explanatory notes in one consecutive series by order 
of mention in the text; use superscript Arabic numbers without parentheses. All 
references should be grouped at the end of the manuscript. Author(s) should consult 
The ACS Style Guide, 3rd ed. (ACS: Washington, DC, 2006) for the appropriate style 
to use in citations of journal papers, books, and other publications. In literature 
references, journal abbreviations should be those used by Chemical Abstracts. In the 
web edition of the paper, references will be linked to various electronic sources (the 
corresponding abstract from Chemical Abstracts Service, full text from other ACS 
journals, etc.); therefore, the accuracy of the references is critical. Author(s) are 
responsible for the accuracy of the references. 
 
Nomenclature 
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Registered trademark names should be capitalized whenever used. Usually the 
chemical name or composition should be given in parentheses or in a reference at the 
first occurrence of such a name. Chemical Abstracts (CA) nomenclature rules are 
described in Appendix IV of the Chemical Abstracts Index Guide. For CA 
nomenclature advice, consult the Manager of Nomenclature Services, Chemical 
Abstracts Service, P.O. Box 3012, Columbus, OH 43210-0012. A name-generation 
service is available for a fee through CAS Client Services, 2540 Olentangy River 
Rd., P.O. Box 3343, Columbus, OH 43210-0334 (answers@cas.org). Avoid trivial 
names. Well-known symbols and formulas may be used if no ambiguity is likely. 
Define trade names, abbreviations, and acronyms at point of first use. 
 
Artwork 
Artwork should be sequentially numbered using Arabic numbers. Schemes and 
charts may have titles and footnotes; figures should have captions. Structures should 
be designated with boldface Arabic numbers. Author(s) should remove all colour 
from graphics, except graphics that they would like to be considered for publication 
in colour (see Colour section for details). When inserting illustrations in the 
manuscript, author(s) should follow the web instructions for manuscript preparation. 
For additional guidelines, see “Working with Graphics”, which can be accessed by 
going to http://pubs.acs.org/jpr and clicking on Submission & Review/Info for 
Authors & Reviewers/Information for Authors/Manuscript Preparation and 
Submission. Please note that the quality of the final illustrations depends on the 
quality of the original artwork provided. Figures cannot be modified or enhanced by 
the journal production staff. 
 
Artwork should be provided at the size it will be printed in the journal. To ensure 
good quality production in the journal, the author(s) should print a copy of each 
graphic (at the size desired in the final printed version) to verify that all parts of the 
artwork are clear and legible. Any changes to the artwork (including size changes) 
must be made in the drawing program that was used to create the artwork, and the 
revised artwork must be reimported into the manuscript. Artwork should be 
constructed in keeping with the journal column widths—one column (which is 
preferred): maximum of 8.5 cm (3.3 in.); two columns: minimum of 10.5 cm (4.1 in.) 
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and maximum of 17.8 cm (7.0 in.); total height for one or two columns: 24 cm (9.5 
in.). 
 
In preparing artwork, ensure that 
• the lettering is 4.5 pt or larger and is in Helvetica or Arial font, 
• the lines are no thinner than 0.5 pt, 
• the lettering and the lines are of uniform density, and 
• dark black ink is used to achieve the best contrast. 
 
Use a simple cross-hatch design to show a pattern or to achieve a 3-D effect. Do not 
submit colour prints when the artwork will be reproduced in black and white. 
 
Supporting Information 
Almost any type of supplementary figures or data (reproductions of spectra, 
experimental procedures, tabulated data, expanded discussion of peripheral findings, 
etc.) can be accommodated in Supporting Information. The author(s) should include 
a Supporting Information Available statement at the end of the manuscript. Use the 
following format: “Supporting Information Available: This material is available free 
of charge via the Internet at http://pubs.acs.org.” 
 
Supporting Information must be submitted at the same time as the manuscript and 
uploaded separately to the ACS Paragon Plus Environment. A list of acceptable file 
types is available on the Web. All Supporting Information files of the same type 
should be prepared as a single file (rather than submitting a series of files containing 
individual images or structures). For example, all Supporting Information available 
as PDF files should be contained in one PDF file. 
 
Do not upload figures and tables that are to be published in the article into the 
Supporting Information file. 
 
Manuscript types 
The research pages of the Journal of Proteome Research are devoted to scholarly 
publication encompassing all aspects of systems-oriented protein analysis and 
function. Papers that integrate fields such as chemistry, mathematics, applied 
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physics, biology, and medicine in order to provide better understanding of the 
function of proteins in biological systems are encouraged. Articles may focus on any 
phase of proteome research, including sample preparation, separation, 
characterization, and analysis of proteins (including informatics), as well as the 
development of new methodologies. Papers involving extensive use of computers 
and data processing (e.g., bioinformatics) will be judged by the usual criteria of 
originality, technical content, and value to the field. Detailed mathematical 
derivations, computation procedures, and programs should be presented as 
Supporting Information. If the research involves the use of human or animal samples, 
the author(s) must have permission from their institutions and must conform to 
commonly practiced ethical standards. 
 
In addition to regular research papers, Letters, Technical Notes, Perspectives, 
Reviews, Tutorials, and Rapid Communications are published. 
 
Letters are opinion pieces related to the field of proteomics. Letters can be supported 
by brief descriptions of scientific data and references, but such information is not 
necessary for acceptance. 
 
Technical Notes should be brief descriptions of novel apparatus or techniques that 
offer definite advantages over those already available. These papers should 
demonstrate real ingenuity on the author(s)’ part. Technical Notes have a maximum 
length of 8 journal pages (8000 words).  
 
Perspectives articles are unlike others in the research section in that they are not 
reports of original research or reviews with the traditional objective of summarizing 
progress in a field. Instead, Perspectives point out the author(s)’ vision of the 
character and importance of a new direction in proteome research. They are aimed at 
specialists and experts in the field, and the level of writing reflects their 
sophistication with the topic. They are not intended to be accounts or analyses of an 
individual’s personal research. Perspectives can be submitted without invitation; 
some will be invited. Author(s) are encouraged to suggest experts in the field who 
can review their Perspectives. Because only a limited number of Perspectives will be 
published, the Editor recommends a preliminary contact by prospective author(s). 
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Editorial decisions will be based on technical quality, significance, and 
demonstration of a new direction in proteome research. 
 
Reviews are thoroughly documented, peer-reviewed assessments of selected areas of 
proteome research literature for the purpose of identifying critical research needs. 
Reviews can be longer than the typical research article but should generally be 
limited to 9000 words, including references, graphs, and figures. Critical reviews 
should increase readers’ knowledge through discriminating comparisons and 
insightful organization of the material. A mere listing of literature citations with 
descriptive comments is inadequate. Criteria for acceptability include current 
importance of the field under review, thoroughness of the literature coverage, clarity 
of text, and clear identification of research needs.  Tutorials are articles written for 
researchers who are new to the field of proteomics. These articles cover timely topics 
but do not necessarily present new data. Compared to Reviews, Tutorials are 
narrower in scope and should more fully explain the relevant background of the 
topic. The editors consider these articles important for the journal’s educational 
mission.  
 
Tutorials are typically 3000—6000 words long, though they could be longer in some 
cases. Although many Tutorials are invited, unsolicited submissions will be 
considered. 
Rapid Communications are concise accounts of work that is especially time-
sensitive. To expedite the handling of these manuscripts, authors should take care to 
submit papers that will not require revision. In addition, ~2 weeks before submitting 
a paper, the corresponding author should contact the editorial office with the names 
of suggested reviewers. 
 
File preparation for manuscript revisions 
Author(s) are encouraged to use the template for their electronic version. In 
manuscript preparation, use the document mode or its equivalent in the word-
processing program; that is, do not save files in “Text Only” (ASCII) mode. If a non-
Western version of a word-processing program was used to prepare the manuscript, 
save the file in rich-text format (RTF). The text should be left-justified, and 
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automatic end-of-line hyphenation should be turned off. Use “returns” only to end 
headings and paragraphs, not to break lines of text. Do not insert spaces before 
punctuation. References must conform to the format printed in the journal. 
Characters must be correctly represented throughout the manuscript: for example, 1 
(one) and l (ell), 0 (zero) and O (oh), x (ex) and × (multiplication sign). Check the 
final copy carefully for consistent notation and correct spelling. The Editorial Office 
conversion program will faithfully translate any errors present in a file. The complete 
manuscript should be placed in one file created in one of the word-processing 
programs listed below. All graphics in this file must be given at the size they are to 
be printed in this journal. Proof a printout of the manuscript from a 600-dpi laser 
printer to ensure that all artwork is clear and legible. 
 
Acceptable word-processing packages 
For a list of currently acceptable software and file designations, please refer to the 
submission guidelines presented at http://paragonplus.acs.org. 
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PART D 
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University of Cape Town Dissertation Guidelines 
Minimum Requirements for Dissertations for MMed and MPhil for 
Subspecialities Degrees 
 
Following extensive discussion with Heads of Divisions, Dr S Kalula and Prof S 
Kidson recommend the following minimum criteria for dissertations for MMed and 
MPhil (subspeciality) degrees: 
 
The MMed minor dissertation (or the MPhil dissertation in the case of sub-
specialities) is one of three examination components of the MMed/MPhil degree. 
This minor dissertation carries one third of the weight of a full master’s dissertation 
in terms of its credit weighting. 
 
The dissertation must be a study containing the results of an analytical, quantitative, 
or 
epidemiological study carried out by the candidate (for certain disciplines, the 
candidate may chose instead to do a qualitative study, an audit cycle or a formal 
systemic review). A case report is not acceptable for the dissertation. 
 
The dissertation must be the result of independent work of the candidate conducted 
under the guidance and direction of a supervisor(s) and should demonstrate evidence 
of an ability to undertake research, to adequately interpret results and to 
comprehensively and critically review the relevant literature. Although the findings 
of the research need not necessarily be original, they must be seen to advance 
scientific understanding. The topic and scope of research will depend on the 
particular disciplines and must be agreed upon in consultation with the supervisor(s). 
 
Research Protocol 
Candidates intending to register for the MMed/MPhil Part III are required to submit a 
full research protocol for approval to their respective Departmental Research 
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Committee (DRC). The candidate must also obtain FHS UCT Ethics approval prior 
to conducting their research. This full research protocol (together with a copy of the 
ethics approval letter) must be submitted to the postgraduate administration for 
approval by the Board of the Faculty of Health Sciences, prior to commencement of 
the research. For most disciplines, submission of the research protocol should be 
made no later than the end of year 2. 
 
The research protocol should outline the scope and content of the dissertation and 
must include the title of the proposed dissertation, name of the supervisor(s) and their 
brief curriculum vitae. 
 
Submission of Dissertations 
On completion, the dissertation should be submitted to the Faculty Postgraduate 
Officer. The candidate should inform the Faculty Officer one month in advance of 
the intention to submit. 
Submission deadlines: 
1. March 15th for June graduation 
2. August 15th for December graduation 
 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter 
supporting submission. This letter should be supplied by the primary supervisor. If 
this supervisor is external, the internal supervisor must be kept informed at every 
stage of the process. Specific submission requirements may be set by individual 
disciplines. 
 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the 
beginning of the first quarter (first day of academic year), and before the start of the 
second semester (mid July) to qualify for a 50% fee rebate. 
 
SUPERVISORS 
One cannot overemphasize the importance of identifying a dissertation supervisor as 
early as possible. The supervisor should be an individual who can relate to the 
candidate’s research project, be available for frequent and regular discussion and 
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advice, and someone with whom the candidate can develop a good working 
relationship. Where specialised equipment and/or laboratory work is required for the 
study, the supervisor should assist in facilitating such access to such facilities. 
Supervisors may assist candidates in developing scientific communication skills but 
they are not required to do detailed editing or correction of spelling, grammar, or 
style. They may refer candidates to the UCT Writing Centre for this purpose. 
 
The primary supervisor may be based outside the candidate’s home department, 
faculty or university. In such a case, an internal (or secondary) supervisor will be 
required in addition to the primary supervisor, to serve as a guide and link to 
discipline-specific procedures. Primary supervisors retain responsibilities to the 
candidate and the university until the dissertation process is complete. 
 
Please note: in order to assist a candidate with a master’s research topic the 
supervisor needs to hold a master’s degree or higher, or have relevant research 
experience. If the primary supervisor does not hold a higher degree or equivalent 
(such as a Fellowship of The College of Medicine of South Africa), then a secondary 
supervisor who has a higher degree will need to be appointed in addition to the 
primary supervisor. 
 
Candidates are strongly encouraged to publish the study with the supervisor(s) as co-
author(s). This may require work beyond the graduation date. Such arrangements 
should be discussed and documented in advance. 
 
The Dissertation 
Submission of the dissertation should satisfy the following criteria: 
1. The title page should contain the candidate’s name, dissertation title and the 
name of the university.  It must also state the degree, e.g. Master of Medicine 
(MMed) in Public Health Medicine,  Occupational Medicine, Family 
Medicine, Surgery, etc. The title page should also include a statement to the 
effect that the research report is based on independent work performed by the 
candidate and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree to any other university. It must 
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also state that this work has not been published prior to registration for the 
abovementioned degree. 
 
2. The body of the dissertation, which must be structured in 4 parts, should 
include the following: 
 
Part A: The protocol (as approved by the Departmental Research Committee 
and Faculty Research Ethics Committee). The protocol should not exceed 
4000 words. 
 
Part B: A structured literature review appropriate to the subject matter and 
methods of the dissertation. The literature review must, amongst other things, 
show that the student is sufficiently acquainted with the relevant literature 
and is able to perform a critical appraisal and, if appropriate for the topic, 
show a good understanding of evidence-based medicine. 
 
The review should be between 3 000 and 4 000 words. 
 
A suggested structure for the literature review is as follows: 
a) Objectives of literature review 
b) Literature search strategy, including inclusion and exclusion criteria 
c) Quality criteria - some leeway will be allowed here, as candidates 
will vary in their ability to appraise studies. This will also vary with 
the nature of the dissertation. 
d) Summary or interpretation of literature 
e) Identification of gaps or needs for further research 
f) References (which will overlap with but will not be the same lists as 
in the journal article and protocol) 
 
Part C: The results of the study must be presented in the form of a manuscript 
of an article for a named peer reviewed journal, meeting all the requirements 
set out in the “Instructions for Authors” of that journal, including the word 
count and referencing style. (Unless specially motivated, the journal chosen 
will need to allow for at least 3000 words excluding abstract, tables, figures 
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and references). The “Instructions to Authors” of the journal must be 
appended. The journal chosen for publication must be appropriate to the 
subject matter of the dissertation and accredited by the Department of 
Education or listed in the citation index of the Institute for Scientific 
Information (ISI). 
Important note: the candidate need not have submitted the article, not is the 
acceptance of the article and requirement for passing the degree. The norm of 
practise is to publish the study with the supervisor(s) as co-author(s) and 
candidates are strongly encouraged to submit their manuscript either before 
or after examination of the mini-dissertation. 
 
Part D: All supporting documents including: 
• Questionnaire/data capture instrument 
• Consent forms and any related participant information sheets 
• Technical appendices, including, if considered necessary, any 
additional tables not included in the main manuscript for the examiner 
to have available. These should be accompanied by a brief narrative. 
• Official Ethics approval letter from the Faculty Research Ethics 
Committee 
 
3. The article does not have to be submitted to the journal in order to meet 
academic requirements. 
 
4. A candidate must submit 2 copies of the dissertation in temporary binding, 
and an electronic copy on compact disc in a universally readable format (e.g. 
pdf). 
 
Examiners 
The full dissertation will be submitted for examination through the Postgraduate 
office of our Faculty to two external examiners (nominated by the supervisors and 
HOD).Three examiners will be nominated, two of which are invited to examine, and 
one held as an alternate. All examiners must be external to UCT. These nominations 
are circulated to the Faculty Dissertation Committee. It is the supervisor’s (or co-
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
DAVID HAARBURGER – HRBDAV002 – MMED (Chemical Pathology)   72 
supervisor’s) responsibility to submit names of potential examiners to the Faculty 
Officer when the candidate is ready to submit. 
 
The examiners will be well briefed regarding the specific requirements and criteria 
for submission and examination of the mini-dissertation. Such criteria will clearly 
explain the difference between the minidissertation and a Master’s degree by 
dissertation alone. 
 
Details required for each examiner are: academic qualifications, postal and/or 
physical address, telephone and fax numbers and e-mail address, and one paragraph 
description of their standing in the relevant field (drawn from their CV if need be.) 
 
The candidate may not be informed of the identity of the examiners. After the 
outcome of the minidissertation has been finalised, the examiners’ identities are 
made known if the examiners have indicated that they do not object to this. 
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Consent Form (English) 
 
DEPARTMENT OF CHEMICAL PATHOLOGY 
UNIVERSITY OF CAPE TOWN 
 
CONSENT FORM 
 
BIOMARKER DISCOVERY IN HIV/AIDS USING PROTEOMICS 
 
Often, when blood is analyzed from people with a particular disease, 
differences are noted in various protein concentrations.  These 
concentration differences can sometimes be used to diagnose a 
disease or tell how serious that disease is.  The purpose of this study 
is to establish whether there are any differences between protein 
concentrations found in the blood of HIV positive and HIV negative 
people. These differences may prove to be useful in future HIV testing. 
 
The blood that is being taken from you will be tested for HIV and then 
analyzed for different protein concentrations. 
 
I, ………………………………………………………, agree to participate 
in the above study and hereby give permission that blood may be 
taken and serum analysed and/or stored.  
 
I understand that I will undergo the following investigations: 
 
i. Venous blood will be taken for a HIV test and the 
measurement of serum proteins 
ii. I further understand that a portion of these blood samples 
will be stored for: 
a) possible reanalysis 
b) analysis when the study is completed, if additional 
information has become available 
c) further research purposes, subject to the approval of 
the University of Cape Town Research Ethics 
Committee and that any information from such 
research will remain confidential 
d) I understand the results of these tests will not become 
available to me 
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I have been informed that:   
a) the investigators are under the obligation to respect 
medical confidentiality  
b) No DNA will be stored and no genetic/DNA tests will be 
done on these samples 
c) All samples will be anonymised prior to being sent to 
the laboratories.   
 
I UNDERSTAND THAT THIS STUDY WILL BE OF NO BENEFIT TO ME 
AND ONCE MY BLOOD HAS BEEN TAKEN, THERE WILL BE NO WAY TO 
TRACE IT BACK TO ME. 
 
 
 
ALL OF THE ABOVE HAVE BEEN EXPLAINED TO ME IN A LANGUAGE 
THAT I UNDERSTAND AND MY QUESTIONS HAVE BEEN ADEQUATELY 
ANSWERED 
 
 
 
Participant: Name  …..………………………… Date: ……………….. 
 
 
 
Participant: Sign …….....……………………. Date: ……………….. 
 
 
 
Informed consent obtained by: Name ………………………….  
      Sign  …………………………. 
 
 
 
Witness: …………………………………… Sign: ….…..………. 
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Consent Form (Xhosa) 
 
ISEBE LENZULULWAZI NGEZIFO EGAZINI 
IDYUNIVESITHI YASEKAPA 
 
IFORM YOKUCELA IMVUME  
 
UKUPHANDWA NZULU NGESIFO IHIV/AIDS KUSETYENZISWA 
IPROTEOMICS 
 
Ngamaxesha amaninzi xa kuphononongwa igazi labantu abanesifo 
esithile, umahluko uyabonakala kwi proteins egazini. Lo mahluko 
kwezi proteins uyasetyenziswa ukuxela ukuba sikhona esisifo okanye 
hayi, kwaye ziyakwazi nokubonisa ukuba esisifo singanobungozi 
kangakanani na. Oluphando nzulu lwenziwayo linganceda ekuhlolweni 
kwegazi xa kukhangelwa intsholongwane iHIV. 
 
Sicela uthathe inxaxheba koluphando nzulu ngokusivumela sitsale 
igazi lakho, silihlolele intsholongwane ye HIV siphinde silihlolele 
ezinye iproteins ezinobakhona egazini, kusetyenziswa iproteomics 
ngaba baphandi nzulu bangentla. 
 
Mna,……………………………………………………,ndiyavuma 
ukuthatha inxaxheba koluphando nzulu, ndinikeza ababaphandi 
imvume youkutsala igazi lam ukuze lihlolwe, liphononongwe 
kusetyenziswa iproteomics.  
 
Ndixelelwe kwaye ndiyazi ukuba ndizakuhlolwa ngoluhlobo: 
 
iii. Igazi lam lizakutsalwa lihlolelwe intsholingwane iHIV kunye 
nezinye iproteins ezinokuthi zibekhona egazini. 
iv. Kwaye ndiyaqonda ukuba eligazi lizakugcinwa ngaba 
baphandi nzulu ukwenzela: 
 
a) Liphinde lihlolwe xa ikhona imfuneko yokwenza oku. 
b) Liphinde lihlolwe xa oluphando nzulu sele lugqityiwe 
ukuba zikhona indlela ezintsha ezivelayo zokuhlola 
igazi. 
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c) Abanye abaphandi nzulu bakwazi ukulisebenzisa, 
kodwa phambi kokuba lisetyenziswe, iUniversity of 
Cape Town Research Ethics Committee  kufuneka 
ibanike imvume nabo benze isithembiso sokuba 
iziphumo zalamagazi zihlala zilihlebo labaphandi 
kuphela. 
d) Ndixelelwe kwaye ndiyazi ukuba iziphumo nengxelo 
zalamagazi andizikuzixelelwa. 
 
 
 
 
Ndixelelwe ukeba:   
a) Ababaphandi nzulu basenzile isithembiso sokugcina 
ingxelo, neziphumo zamagazi zilihlebo.  
b) Akukho DNA izakugcinwa kwaye akukho phando 
lweDNA okanye genetics luzakwenziwa kweli gazi. 
c) Eligazi lizakugcinwa luyimfihlo yabaphandi nzulu. 
 
NDIYAZI UKUBA OLUPHANDO NZULU ALUZUKUTSHINTSHA NTO 
KUHLOBO ENDIKHATHALELWA NGAYO KULE KLINIKI KWAYE XA SELE 
LITHATHIWE AKUSOZE KUBEKHO NDLELA YOUKUTHI LELAM. 
 
 
 
ZONKE EZINKCUKACHA ZINGENTLA ZICACISIWE KUM NGOLWIMI 
ENDILAZIYO KWAYE YONKE IMIBUZO EBENDINAYO IPHENDULWE 
NGENDLELA EYONELISEKAYO. 
 
 
 
Umthati nxaxheba: Igama…………………… Umhla:……………….. 
 
 
 
Umthathi nxaxheba: Sayina.…………………     Umhla:……………….. 
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Imvume youkuthatha inxaxheba icelwe ngu: Igama
 ………………………….            
Sayina …………………………. 
 
 
 
Ingqina: …………………………………… Sayina.…..………. 
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Phlebotomy Protocol 
 
DEPARTMENT OF CHEMICAL PATHOLOGY 
UNIVERSITY OF CAPE TOWN 
 
PROTOCOL 
 
BIOMARKER DISCOVERY IN HIV/AIDS USING PROTEOMICS 
 
Subjects 
 Blood is required from 30 HIV positive and 30 HIV negative 
individuals. 
 Blood is to be collected from Xhosa males aged 21 to 35 years. 
 Participants must not be on any medical treatment. 
 Participants must not have any significant medical history, in particular  
participants must be free from: 
o Diabetes 
o Kidney disease 
o Liver disease 
o Heart disease 
o Infection or inflammatory conditions (other than HIV) 
o Any major systemic illness 
o Any signs or symptoms that may indicate an undiagnosed 
disease. 
 
 
Phlebotomy 
 Blood should ideally be collected from the left cubital fossa in a seated 
position. 
 After the area has been cleaned, a tourniquet may be applied to make 
venipuncture easier. 
 The time between applying the tourniquet and collecting the blood 
must be minimized. 
 Blood must be collected into a 5ml SST (yellow top) tube.  The tube 
must be filled if possible. 
 
Storage and Transport 
 Once collected, the blood should be stored at room temperature. 
 The blood must reach the laboratory within six hours. 
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 At the laboratory the serum must be separated (4000rcf for 5 minutes) 
and frozen at -20ºC. 
 
 
Thank you for participating in this study! 
 
 
 
 
Please contact me if you have any queries: David Haarburger (021) 404-4135 
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Ethics Approval 
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Supplementary Figures 
 
Figure S1. Gels from HIV-positive subjects 
Silver-stained two-dimensional electrophoresis gels of HIV-positive subjects.  
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Figure S2.  Gels from HIV-negative subjects 
Silver-stained two-dimensional electrophoresis gels of HIV-negative subjects.  
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Mass Spectrometry Data 
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